[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognitive-performance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognitive-performance":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,60,87,115,149,171,197,224,266,312,334,365,391,413,453,480],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":34,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100053649","phosphatidylserine-taurine-and-caffeine-for-cognitive-fatigue-in-professional-football-players-100053649",false,"NCT07696052","Phosphatidylserine, Taurine, and Caffeine for Cognitive Fatigue in Professional Football Players","Neurocognitive Fatigue Resistance, Visual Search Efficiency, and Tactical Decision-Making After Phosphatidylserine-Containing Taurine-Caffeine Supplementation in Professional Male Football Players","TCPS-Foot","Inclusion Criteria:\n\n* Male professional outfield football players aged 18 to 37 years.\n* First-team players or selected U19 players aged 18 years or older who are regularly integrated into first-team training.\n* Regular participation in club training.\n* At least 5 years of systematic football training experience.\n* Free from injury or illness limiting full participation in training and testing.\n* Normal or corrected-to-normal vision.\n* Ability to complete the laboratory and field-based testing procedures.\n* Written informed consent provided before participation.\n\nExclusion Criteria:\n\n* Goalkeepers.\n* Current injury or illness limiting full participation in testing.\n* Neurological disease.\n* Recent concussion or head trauma.\n* Uncorrected visual impairment.\n* Use of phosphatidylserine, nootropic agents, or strong stimulants during the previous 4 weeks.\n* Non-standard caffeine intake on testing days.\n* Failure to comply with pre-test standardization procedures.\n* Failed eye-tracker calibration.\n* Loss of more than 30% of gaze data during the football-specific decision-making task.\n* Withdrawal of consent.",true,"MALE","18 Years","37 Years",{"count":22,"type":23},62,"ESTIMATED","INTERVENTIONAL",[26],"NA","This randomized, double-blind, placebo-controlled, parallel-group trial will evaluate the effects of 14 days of taurine-caffeine supplementation with or without phosphatidylserine on neurocognitive fatigue resistance, visual search efficiency, and football-specific tactical decision-making in professional male football players. Sixty-two male outfield football players from two professional clubs will be randomized to placebo, taurine plus caffeine, or taurine plus caffeine plus phosphatidylserine. Laboratory and field-based outcomes will be assessed at baseline and after the supplementation period.",[29,30,31,32,33],"Mental Fatigue","Cognitive Performance","Athletic Performance","Soccer Performance","Decision Making",[35,36,37,38,39,40,41,42,43,44,45,46],"Phosphatidylserine","Taurine","Caffeine","Football Players","Soccer","Neurocognitive Load","Visual Search","Eye Tracking","Tactical Decision-Making","Stroop Flanker Task","Reactive Passing Decision Test","Sports Nutrition","NOT_YET_RECRUITING","2026-07-09",{"date":50,"type":51},"2026-07-13","ACTUAL",{"date":53,"type":23},"2026-07",{"date":55,"type":23},"2026-08",{"name":57,"class":58},"Vizja University in Warsaw","OTHER",2,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":66,"minAge":19,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":24,"phases":69,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100645264","examining-the-efficacy-of-short-term-intensive-ptsd-treatment-on-psychological-and-cognitive-impairment-symptoms-100645264","NCT07680517","Examining the Efficacy of Short-Term Intensive PTSD Treatment on Psychological and Cognitive Impairment Symptoms","Inclusion Criteria:\n\n-Treatment-seeking military personnel (i.e., any assigned or aligned JSOC personnel) who meet diagnostic criteria for PTSD or subthreshold PTSD (i.e., meeting diagnostic threshold for 3 of 4 symptom criteria who are (1) 18 years of age or older; (2) current diagnosis of PTSD or subthreshold PTSD (i.e. meeting diagnostic criteria for 3 of 4 symptom criteria, assessed using the DIAMOND); (3) current military personnel; (4) ability to speak and understand the English language; and (5) ability to complete the informed consent process\n\nExclusion Criteria:\n\n* (1) substance use disorder requiring medical management; (2) imminent suicide risk warranting inpatient hospitalization or suicide-focused treatment; and (3) impaired mental status that precludes the ability to provide informed consent (e.g., intoxication, psychosis, mania).","ALL",{"count":68,"type":23},120,[26],"Our long-term goal is to provide rapid and sustained reductions of trauma and cognitive-related symptoms among Special Operations personnel with PTSD or subthreshold PTSD. The primary objective of this project is to examine the effectiveness of massed PTSD treatment (i.e., CPT and EMDR) in \"real-world\" military settings. CPT and EMDR are both empirically supported psychotherapies for PTSD. To accomplish this objective, we will enroll military personnel meeting diagnostic criteria for PTSD or subthreshold PTSD (i.e., meeting threshold levels for 3 of 4 symptom criteria).",[72,30],"PTSD",[72,74,75],"CPT","Military","RECRUITING","2026-06-25",{"date":79,"type":51},"2026-07-02",{"date":81,"type":51},"2026-04-01",{"date":83,"type":23},"2028-08",{"name":85,"class":58},"Ohio State University",1,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":17,"sex":66,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":24,"phases":97,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":59},"100622778","a-clinical-trial-to-investigate-the-safety-and-efficacy-of-ap-brain-on-cognitive-performance-at-varying-dosages-in-healthy-middle-aged-and-older-adults-with-self-reported-memory-problems-100622778","NCT07388043","A Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Performance at Varying Dosages in Healthy Middle-aged and Older Adults With Self-reported Memory Problems","A Randomized, Triple-blind, Placebo-controlled, Parallel, Proof of Concept Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Performance at Varying Dosages in Healthy Middle-aged and Older Adults With Self-reported Memory Problems","Inclusion Criteria:\n\n1. Males and females 40-79 years of age, inclusive\n2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening\n\n   Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n   * Abstinence and agrees to use contraception if planning on becoming sexually active\n3. Individuals with self-reported memory problems as assessed by a combined score of ≥6 from the memory assessment questions provided at screening\n4. Absence of dementia or other significant cognitive impairment as assessed by MMSE-2 score of ≥24 at screening\n5. Agrees to avoid high sources of caffeine (e.g., supplements, tea, coffee, energy drinks), NSAIDs, and alcohol consumption for 24 hours prior to post-screening clinic visits\n6. Agrees to avoid first generation anti-allergy medication for 48 hours prior to post-screening clinic visits\n7. Agrees to avoid moderate-vigorous exercise 12 hours prior to post-screening clinic visits\n8. Agrees to avoid travel across two or more time zones two weeks prior to any study visit\n9. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study\n10. Willing and able to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits\n11. Provided voluntary, written, informed consent to participate in the study\n12. Healthy as determined by medical history, laboratory results, and vital signs, as assessed by the QI\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity, or intolerance to the investigational product or placebo ingredients\n3. Self-reported confirmation of any significant neuropsychological condition and\u002For cognitive impairment (e.g., attention-deficit\u002Fhyperactivity disorder, Schizophrenia, bipolar disorder, post-traumatic stress disorder, brain injury, neurodegenerative disease, infections, insomnia, depression, epileptic or other seizure-related disorders) that could interfere with study participation as assessed by the QI\n4. Self-reported color blindness\u002Fweakness as assessed by the QI\n5. Individuals who consume high caffeine daily or are addicted to caffeine at screening as assessed by the QI\n6. Current employment that calls for overnight shiftwork as assessed by the QI\n7. Unstable metabolic disease or chronic diseases as assessed by the QI\n8. Current or history of significant diseases of the gastrointestinal tract or conditions that result in malabsorption, as assessed by the QI\n9. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (See Section 7.3.1)\n10. Type I diabetes\n11. Type II diabetes if on insulin treatment. Type II diabetics on stable medication for at least three months and an HbA1c of \\\u003C8.0% may be included after assessment by the QI on a case-by-case basis\n12. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n13. History of or current diagnosis with kidney, gallbladder (e.g., gallstones, bile duct obstruction), and\u002For liver diseases (e.g., reduced bile salts, SIBO) as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n14. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n15. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n16. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n17. Individuals with an autoimmune disease or are immune compromised as assessed by the QI\n18. Self-reported confirmation of a HIV-, Hepatitis B- and\u002For C-positive diagnosis as assessed by the QI\n19. Self-reported confirmation of blood\u002Fbleeding disorders as assessed by QI\n20. Use of medical cannabinoid products\n21. Chronic use of cannabinoid products (\\>2 times\u002Fweek). Occasional users will be required to washout and abstain for the duration of the study period\n22. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n23. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n24. Alcohol or drug abuse within the last 12 months\n25. Current use of prescribed and\u002For OTC medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy and\u002For safety of the investigational product (Sections 7.3.1 and 7.3.2)\n26. Current or previous use of cognitive training programs or therapies, as assessed by the QI\n27. Clinically significant abnormal laboratory results at screening as assessed by the QI\n28. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit\n29. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n30. Individuals who are cognitively impaired and\u002For unable to give informed consent\n31. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant","40 Years","79 Years",{"count":68,"type":23},[26],"The goal of this clinical trial is to investigate the safety and efficacy of AP-Brain on cognitive performance at varying dosages in healthy middle-aged and older adults with self-reported memory problems. The main question it aims to answer is:\n\nWhat is the effect of AP-Brain at 1 g, 3 g, and 5 g on cognitive performance?\n\nParticipants will be asked to consume AP-Brain at 1 g, 3 g, or 5g, or Placebo and asked to complete memory assessment questionnaires.",[100,30],"Cognition",[102,103,104],"Memory","AP-Brain","cognitive performance","2026-06-19",{"date":107,"type":51},"2026-06-24",{"date":109,"type":23},"2026-06",{"date":111,"type":23},"2026-11",{"name":113,"class":114},"Rousselot BVBA","INDUSTRY",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":17,"sex":66,"minAge":19,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":24,"phases":126,"briefSummary":127,"conditions":128,"keywords":131,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":86},"100642883","effects-of-caffeine-on-chess-performance-and-cognitive-function-in-professional-chess-players-100642883","NCT07641335","Effects of Caffeine on Chess Performance and Cognitive Function in Professional Chess Players","GRANDMASTER: Gauging the Role of Alertness and Neurostimulation With Dietary Caffeine in Master-Level Chess; A Double-Blind Randomized Crossover Trial","GRANDMASTER","Inclusion Criteria:\n\n* Male and female professional chess players aged 18-50 years\n* Current Fédération Internationale des Échecs (FIDE) standard rating between 2300 and 2600 Elo, or achievement of a standard FIDE rating within this range during the previous 12 months\n* Habitual caffeine consumers consuming ≤2 cups of coffee per day\n* Willingness to comply with all study procedures and study visits\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Non-caffeine users\n* Habitual caffeine intake exceeding 2 cups of coffee per day\n* Cardiovascular disorders\n* Metabolic disorders\n* Psychiatric disorders\n* Pregnancy or breastfeeding\n* Current smoking\n* Shift workers\n* Use of psychoactive medications\n* Participation in another clinical trial within the previous 3 months\n* Known allergy or intolerance to milk proteins, dairy products, or soy\n* Known red-green color blindness or other color vision deficiencies that may interfere with Stroop Test performance","50 Years",{"count":125,"type":23},12,[26],"This study will examine whether caffeine improves cognitive and competitive performance in professional chess players during tournament-style games. In a randomized double-blind crossover design, participants will complete two experimental sessions in which they consume either caffeinated coffee or decaffeinated coffee before playing a standardized chess match. Cognitive performance will be assessed using attention and reaction-time tests, including the Stroop Test, Trail Making Test, and Puzzle Rush task. Chess performance outcomes such as move accuracy, time management, and error rates will also be evaluated. The study aims to determine whether moderate caffeine intake enhances focus, alertness, and decision-making during prolonged competitive chess play.",[30,129,130,37],"Attention","Reaction Time",[37,132,30,129,29,133,33,134,135,136,137,138,139],"Chess Performance","Professional Chess Players","Neurocognitive Performance","Randomized Crossover Trial","Coffee","Alertness","Executive Function","Cognitive Fatigue","2026-06-08",{"date":142,"type":51},"2026-06-11",{"date":144,"type":23},"2026-06-15",{"date":146,"type":23},"2027-08",{"name":148,"class":58},"St. Louis University",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":17,"sex":66,"minAge":19,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":24,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":167,"leadSponsor":169,"locationsCount":86},"100637260","cognitive-responses-to-acute-breath-hold-diving-training-in-female-divers-100637260","NCT07616804","Cognitive Responses to Acute Breath-Hold Diving Training in Female Divers","Investigation of Cognitive Responses to Acute Breath-Hold Diving Training in Female Divers","Inclusion Criteria:\n\n* Licensed breath-hold or free-diving athletes\n* Aged between 18 and 30 years\n* Minimum of 5 years of training experience\n* No known cardiovascular or pulmonary disease\n* Non-smokers\n* Willing to participate voluntarily\n* Refraining from intense exercise within 24 hours before testing\n\nExclusion Criteria:\n\n* Use of performance-enhancing drugs or ergogenic aids\n* Presence of chronic sports injury\n* Alcohol consumption within 24 hours before testing\n* Caffeine intake within 2 hours before testing\n* Sleep deprivation or severe fatigue\n* Current medication use Fear of water or inability to complete breath-hold procedures","30 Years",{"count":158,"type":23},30,[26],"This study aims to investigate the acute cognitive and physiological responses to breath-hold diving training in trained female divers. Participants will complete three separate sessions including a control session, a land-based breath-hold training session, and a water-based breath-hold training session in randomized order. Cognitive performance, mood state, heart rate responses, respiratory function, and maximal breath-hold capacity will be evaluated before and after the interventions. The study is expected to improve understanding of how acute apnea-based diving exercises influence cognitive functions and physiological adaptations under different environmental conditions.",[162,30],"Sport Physiology","2026-05-27",{"date":165,"type":51},"2026-06-01",{"date":165,"type":23},{"date":168,"type":23},"2026-09-15",{"name":170,"class":58},"Istanbul Gelisim University",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":66,"minAge":19,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":181,"phases":4,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":86},"100489440","post-stroke-cognitive-impairment-100489440","NCT05653141","Post-stroke Cognitive Impairment","Prediction of Post-stroke Cognitive Decline and Dementia: Impact of Cognitive Reserve and Post-stroke Life Style","CogStroke","Inclusion Criteria:\n\n* Age ≥18 years old\n* First-ever anterior circulation ischemic stroke confirmed by routine MRI\n* Time of enrollment: ≤ 10 days from stroke onset.\n\nExclusion Criteria:\n\n* Previous stroke anamnestic or based on clinical imaging\n* Additional stroke in posterior circulation\n* Conditions that preclude the cognitive testing (e.g. delirium, intubation, reduced vigilance\n* Neurological or psychiatric conditions that preclude the data interpretation (e.g. pre-stroke dementia, schizophrenia, brain tumor, regular intake of benzodiazepine, depression)\n* MRI contraindication\n* Native language other than German, French or Italian",{"count":180,"type":23},600,"OBSERVATIONAL","Present study aims to track the post-stroke cognitive trajectories and to investigate its inter-individual variability.",[184,30],"First-ever Ischemic Stroke",[186,187],"Ischemic stroke","Cognitive reserve","2026-04-29",{"date":190,"type":51},"2026-05-06",{"date":192,"type":51},"2020-12-17",{"date":194,"type":23},"2029-10-31",{"name":196,"class":58},"Roza Umarova",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":17,"sex":66,"minAge":19,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":24,"phases":206,"briefSummary":207,"conditions":208,"keywords":212,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":86},"100624268","eeg-guided-binaural-beat-audio-to-reduce-performance-related-stress-and-improve-cognition-100624268","NCT07407426","EEG-Guided Binaural Beat Audio to Reduce Performance-Related Stress and Improve Cognition","Effects of EEG-guided Binaural Beat Audio Intervention on Brain Reactivity Associated With Performance-related Stress and Cognition Among Professional Musicians: A Randomized, Double-blinded, Sham-controlled Functional Neuroimaging Trial","Inclusion Criteria:\n\n* Adults (18+ years) enrolled as undergraduate music majors at Texas Tech University\n* Currently preparing for an upcoming concert performance within the next 3 months\n* Able to read standard musical notation\n\nExclusion Criteria:\n\n* Subjects with contraindications to undergo MRI after being screened by the TTNI safety screening sheet - specifically, Subjects with implanted devices that are not compatible with MRI including, but not limited to cardiac pacemakers, cardiac defibrillators, aneurysm clips, carotid artery vascular clamps, implanted nerve stimulators (neuron-stimulators also called TENS or wires), bone growth or bone fusion stimulators, cochlear implants, vagus nerve stimulators, filters for blood clots (Umbrella, Greenfield, bird's nest), embolization coils (e.g. Gianturco) in the brain, ocular implants, vascular stents, medication pumps, medication patches delivering medications, implanted limbs, ventricular shunts, metal joints, rods, plates, pins, screws, nails, or clips, penile implants, or contraceptives devices including IUDs, cervical pessaries and diaphragms Subjects who have undergone cataract surgery Subjects who have shrapnel or metal in the head, eyes or skin Subjects with a history of working with metal fragments ( or have had metal removed from eyes Subjects with gunshot wounds or BB gun injury Subjects with permanent metal body piercings or jewelry that cannot be removed Subjects who use hearing aids or have braces \u002F permanent retainers that cannot be removed temporarily for the MRI scans Subjects with large tattoos in the head and neck area Subjects with claustrophobia Subjects who are currently pregnant or suspected to be pregnant\n* Physical, medical, neurological or psychiatric impairments (including substance abuse)\n* Current use of medications that could affect cognitive performance (including beta-blockers, stimulants, anxiolytics, antidepressants, or antipsychotics)\n* History of head injury resulting in loss of consciousness\u002Fhistory of brain surgery\n* History of diagnosed hearing impairment or use of hearing aids\n* Current or past diagnosis of epilepsy or seizure disorders\n* Unwillingness or inability to refrain from alcohol consumption 48 hours prior to the study visit\n* Unwillingness or inability to refrain from caffeine consumption 12 hours prior to the study visit\n* Current\u002Fpast history of substance abuse\n* Pregnancy or possibility of pregnancy\n* Unwillingness or inability to follow written, on-screen, and verbal instructions given by the study team",{"count":205,"type":23},32,[26],"Performance-related stress can impair sustained attention, inhibitory control, and memory. This randomized, double-blinded, sham-controlled parallel-arm trial evaluates whether a 30-minute EEG-guided binaural beat audio intervention reduces subjective stress\u002Fperformance anxiety and improves cognition, and whether it changes task-related brain reactivity measured by fMRI. The intervention uses real-time single-electrode EEG recorded over the left prefrontal cortex to dynamically adjust binaural beat frequencies to guide the brain toward a target state; the sham condition uses non-binaural music delivered through identical headphones.\n\nAdult music majors preparing for an upcoming concert will complete pre- and post-intervention fMRI sessions during cognitive\u002Fmusic tasks (Stop Signal Reaction Task, Music Reading Task, Music Memory Retrieval Task) and complete visual analog scales (VAS) assessing performance anxiety, stress, and related subjective states. The primary outcomes include fMRI task-related activity in stress-regulation regions (dlPFC, amygdala, hippocampus), behavioral inhibition indices from the stop-signal task, music memory retrieval accuracy, and VAS-reported stress\u002Fperformance anxiety.",[209,210,211,30],"Cognitive Abilities","Performance","Stress",[213,104,214],"neurofeedback","stress","2026-04-06",{"date":217,"type":51},"2026-04-13",{"date":219,"type":23},"2026-04-07",{"date":221,"type":23},"2026-08-30",{"name":223,"class":58},"Texas Tech University Health Sciences Center",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":17,"sex":66,"minAge":231,"maxAge":232,"enrollmentInfo":233,"targetDuration":4,"studyType":24,"phases":235,"briefSummary":236,"conditions":237,"keywords":244,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":86},"100628795","l-serine-and-strength-training-in-the-elderly-100628795","NCT07466290","L-serine and Strength Training in the Elderly","AAAging","Inclusion Criteria:\n\n* Men and women between the ages of 65 and 85\n* Mini-Mental-State \\>23\n* Independently mobile, without aids (walker, cane, etc.)\n\nExclusion Criteria:\n\n* Chronic diseases that contraindicate medical training therapy\n* Regular strength training (\\>1x\u002Fweek) in the last 6 months before confinement\n* Frailty Index ≥ 3\n* Lack of written consent to test physical performance\n* Regular use of Cortison-containing medications or Antibiotika\n* MR-specific exclusion criteria: claustrophobia, metal equipment or other magnetic Material in or on the body\n* Non-compliance with the study protocol: \\\u003C70% of the planned L-serine administration, \\\u003C70% of the strength training","65 Years","85 Years",{"count":234,"type":23},126,[26],"This study investigates whether taking the amino acid L-serine, either alone or in combination with targeted strength training, can have a positive effect on mental performance, brain function, and physical fitness in older people.\n\nHealthy, independent women and men aged 65 to 85 are eligible to participate. Participants will be randomly assigned to one of three groups: placebo, L-serine, or L-serine combined with strength training.\n\nCognitive tests, physical performance tests, and blood and brain tests will be conducted over a period of 48 weeks. The aim is to gain a better understanding of how nutrition and exercise can contribute to healthy aging.",[238,239,30,240,241,242,100,102,243],"Brain Health","Longevity","Strength Training Effects","Healthy Ageing","Ageing","Muscle Strength",[241,245,246,247,248,249,250,102,251,252,253,254,255,256],"Brain ageing","Older adults","L-serine supplementation","Resistance training","Cognitive function","Cognitive ageing","Hippocampus","Magnetic resonance imaging","Electroencephalography","Brain connectivity","Muscle strength","Synaptic plasticity","2026-03-06",{"date":259,"type":51},"2026-03-12",{"date":261,"type":23},"2026-03",{"date":263,"type":23},"2028-12",{"name":265,"class":58},"University of Vienna",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":17,"sex":66,"minAge":274,"maxAge":275,"enrollmentInfo":276,"targetDuration":4,"studyType":24,"phases":278,"briefSummary":279,"conditions":280,"keywords":289,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":310,"locationsCount":86},"100625406","long-term-effects-of-walnut-consumption-on-brain-function-100625406","NCT07422220","Long-Term Effects of Walnut Consumption on Brain Function","Long-Term Effects of Walnut Consumption on Brain Function in Men and Women With Abdominal Obesity","WalBrain","Inclusion Criteria:\n\n* Men and women, aged between 45-75 years\n* Women postmenopausal: two or more years after last menstruation\n* Waist circumference of ≥102 cm for men and ≥88 cm for women (abdominal obesity)\n* Fasting plasma glucose \\\u003C 7.0 mmol\u002FL\n* Fasting serum total cholesterol \\\u003C 8.0 mmol\u002FL\n* Fasting serum triacylglycerol \\\u003C 4.5 mmol\u002FL\n* Systolic blood pressure \\\u003C 160 mmHg and diastolic blood pressure \\\u003C 100 mmHg\n* Stable body weight (weight gain or loss \\\u003C 3 kg in the past three months)\n* Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeks after completion of the study\n* No difficult venipuncture as evidenced during the screening visit\n\nExclusion Criteria:\n\n* Allergy or intolerance to walnuts\n* Left-handedness (effects on brain function differ between left- and right-handed adults)\n* Current smoker, or smoking cessation \\\u003C 12 months\n* Diabetic patients\n* Familial hypercholesterolemia\n* Abuse of drugs\n* More than 3 alcoholic consumptions per day\n* Use of products or dietary supplements (e.g., dietary fiber or antioxidant dietary supplements (vitamin C and E), fish or seaweed oil capsules) known to interfere with the main outcomes as judged by the principal investigators\n* Use of medication to treat blood pressure, lipid, or glucose metabolism\n* Use of an investigational product within another biomedical intervention trial within the previous 1-month\n* Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases, and rheumatoid arthritis\n* Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident\n* Contra-indications for MRI imaging (e.g., pacemaker, surgical clips\u002Fmaterial in body, metal splinter in eye, claustrophobia)","45 Years","75 Years",{"count":277,"type":23},55,[26],"Rationale: Healthy foods, including mixed nuts, may improve brain function, which is essential for cognitive and metabolic health, and may contribute to improved food intake regulation. It is therefore important to investigate the specific effects of walnuts on cerebral blood flow responses before and after intranasal insulin administration, as well as their associated functional benefits. The investigators hypothesize that long-term walnut consumption improves vascular function and insulin-sensitivity in the brain, thereby enhancing cognitive performance and appetite control in abdominally obese men and women. Objective: The primary objectives are to investigate in abdominally obese adults the effects of 24-week walnut consumption on (regional) vascular function and insulin-sensitivity in the brain, while the investigators will also assess changes in cognitive performance and appetite-related brain reward activity (secondary objectives). Cerebral blood flow responses before (brain vascular function) and after the administration of intranasal insulin spray (brain insulin-sensitivity) will be quantified by the non-invasive gold standard magnetic resonance imaging (MRI)-perfusion method Arterial Spin Labeling (ASL). Study design: This intervention study will have a randomized, controlled parallel design. The total study duration will be 24 weeks. Study population: Fifty-five abdominally obese men and (postmenopausal) women (aged 45-75 years) without a history of cardiovascular diseases or complaints will participate. This study population is expected to have a decreased cerebral blood flow at baseline and are also at increased risk of cognitive impairment, allowing for improvement by the intervention. Intervention: Study participants will receive daily 50 g (about 15% of energy) of raw walnuts (walnut intervention) or no walnuts (control intervention) for 24 weeks. Main study parameters\u002Fendpoints: At baseline and after 24 weeks (follow-up), participants will visit the research facilities for assessments. The primary endpoint is the difference in the cerebral blood flow response before and after intranasal insulin administration between the walnut and control intervention. Cognitive performance will be assessed, while the investigators will also focus on appetite-related brain reward activity (secondary outcomes).",[281,282,283,284,285,286,30,287,288],"Healthy","Brain Insulin Sensitivity","Cerebral Blood Flow","Brain Vascular Function","Satiety and Food Intake","Food Reward","Abdominal Obesity","Cognitive Decline",[290,291,292,293,294,295,296,297,298,299,300,301,302,303],"Walnuts","Juglans","Brain vascular function","Brain insulin sensitivity","Satiety","Food reward mechanisms","Cognitive performance","Abdominal obesity","Cognitive decline","pCASL MRI","fMRI","CANTAB","Intranasal insulin","Food cues","2026-02-18",{"date":306,"type":51},"2026-02-19",{"date":308,"type":23},"2026-02",{"date":146,"type":23},{"name":311,"class":58},"Maastricht University Medical Center",{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":17,"sex":66,"minAge":94,"maxAge":275,"enrollmentInfo":319,"targetDuration":4,"studyType":24,"phases":321,"briefSummary":322,"conditions":323,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":86},"100620260","high-dairy-food-patterns-and-gut-brain-axis-100620260","NCT07355309","High-Dairy Food Patterns and Gut-Brain Axis","Longer-term Effects of High-dairy Food Patterns on the Gut-brain Axis in Adults With Overweight or Obesity","Inclusion Criteria:\n\n* Men and postmenopausal women (≥ 2 years since last menstruation);\n* Aged between 40-75 years;\n* BMI between 25-35 kg\u002Fm2 (overweight or obese);\n* Low-to-moderate habitual dairy consumption (≤ 3 servings\u002Fday);\n* Fasting serum total cholesterol \\\u003C 8.0 mmol\u002FL;\n* Fasting serum triacylglycerol \\\u003C 4.5 mmol\u002FL;\n* Fasting plasma glucose \\\u003C 7.0 mmol\u002FL;\n* Systolic blood pressure \\\u003C 160 mmHg and diastolic blood pressure \\\u003C 100 mmHg;\n* Stable body weight (weight gain or loss \\\u003C 3 kg in the past three months).\n\nExclusion Criteria:\n\n* Left-handedness;\n* Milk protein allergy or lactose intolerance;\n* Current smoker, or smoking cessation \\\u003C 12 months;\n* Familial hypercholesterolemia;\n* Abuse of drugs;\n* Alcoholic intake \\>3 standard drinks\u002Fday;\n* Use of medications, food products or dietary supplements affecting glucose, lipid, or blood pressure regulation, gut microbiota or mental or neurological function, judged by the principal investigator;\n* Use of antibiotics within the previous month;\n* Use of other biomedical investigational products within the previous month;\n* Participation in another clinical trial within the past month;\n* Severe medical conditions including type 2 diabetes, epilepsy, asthma, kidney failure, COPD, inflammatory bowel disease, autoimmune diseases, or rheumatoid arthritis;\n* History of cardiovascular events (e.g., heart attack, stroke) or active cardiovascular disease;\n* Contra-indications for MRI imaging (e.g. pacemaker, metal implants, claustrophobia);\n* Willing to donate blood starting from 8 weeks before the study begins, throughout the study, and for 4 weeks after its inclusion;\n* Difficult to venipuncture as evidenced during the screening visit.",{"count":320,"type":23},40,[26],"Disturbances in brain insulin sensitivity are associated not only with obesity and type 2 diabetes, but also with brain aging and cognitive decline. Longitudinal studies suggest that dietary patterns, particularly those high in dairy intake, may impact brain function via the gut-brain axis. Indeed, dairy foods are known to modulate gut microbiota and may, through this pathway, not only improve brain insulin sensitivity and cognitive performance, but also mental health and appetite regulation. However, underlying mechanisms remain largely unexplored. The primary objective of this study is to evaluate, in older adults with overweight or obesity, the effects of a high-dairy food pattern (4-5 daily servings of (butter)milk, cheese, yogurt, or cottage cheese) compared to a low-dairy food pattern (≤1 serving daily) on (regional) brain vascular function and insulin sensitivity. These outcomes will be quantified using the non-invasive MRI perfusion technique Arterial Spin Labeling (ASL), which assesses cerebral blood flow (CBF) in response to intranasal insulin, a validated physiological marker of brain insulin sensitivity. Secondary objectives include changes in cognitive performance (via the CANTAB neuropsychological test battery), gut microbiota composition (via shotgun metagenomic analysis of fecal samples), and appetite-related brain reward activity (via BOLD-fMRI with food cues). Exploratory analyses include conventional cardiometabolic risk markers (blood pressure, lipid and glucose metabolism), and perceivable (consumer) benefits.",[282,284,283,30,324,325],"Appetite Control","Gut Microbiota","2026-01-12",{"date":328,"type":51},"2026-01-21",{"date":330,"type":23},"2025-12-22",{"date":332,"type":23},"2027-04-01",{"name":311,"class":58},{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":17,"sex":66,"minAge":19,"maxAge":274,"enrollmentInfo":341,"targetDuration":4,"studyType":24,"phases":343,"briefSummary":344,"conditions":345,"keywords":348,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":86},"100553729","lutein-zeaxathin-and-fish-oil-supplementation-100553729","NCT06489873","Lutein, Zeaxathin, and Fish Oil Supplementation","The Role of Lutein, Zeaxanthin, and Fish Oil on Cognitive Function and Bone Health in Healthy Adults","Inclusion Criteria:\n\n* \\\u003C.43 MPOD, a self-reported best-corrected vision of 20\u002F40 or better in each eye, a BMI range of 18.5-30, and meets the inclusion criteria on the preliminary participant questionnaire.\n\nExclusion Criteria:\n\n* allergic to lutein, zeaxanthin, or fish oil, taking supplements with \\>6 mg lutein and\u002For \\>2 mg zeaxanthin for more than two months before study starts, MPOD between \\>.43, self-reported condition of vertigo, diabetic retinopathy, retinitis pigmentosa, optic neuropathy, retinal vascular occlusions, strabismus, autoimmune disorders related to visual health, currently pregnant or trying to become pregnant, history of concussion, vegan (due to gelatin in the placebo), and\u002For taking neuroactive medications, such as Ritalin, Adderall, antidepressants, etc.",{"count":342,"type":23},80,[26],"The goal of this clinical trial is to learn the impact of lutein, zeaxanthin, and fish oil (LZF) supplementation in healthy adults.\n\nThe main question it aims to answer is: Will supplementation with LZF improve macular pigment optical density (MPOD), cognitive performance and bone mass compared to controls after six months?\n\nSubjects with an MPOD \\\u003C.43 will significantly improve MPOD after 6-months of LZF supplementation.\n\nConsuming a LZFO supplement for 6-months will improve visual cognitive performance. Consuming a LZFO supplement for 6-months will improve bone density.\n\nParticipants will be asked to take either a LZF supplement or placebo daily for 6 months.",[30,346,347],"Age-Related Macular Degeneration","Bone Loss",[349,350,351,352,353,354,100,355,30],"Lutein","Zeaxanthin","Fish Oil","Supplement","Macular Pigment","Macular Pigment Optical Density","Age-related Macular Degeneration","2025-09-24",{"date":358,"type":51},"2025-09-30",{"date":360,"type":51},"2024-02-07",{"date":362,"type":23},"2026-05-01",{"name":364,"class":58},"Texas A&M University",{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":372,"enrollmentInfo":373,"targetDuration":4,"studyType":24,"phases":375,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":86},"100605770","exploring-the-cognitive-benefits-of-a-blackcurrant-based-supplement-in-normobaric-hypoxia-100605770","NCT07166835","Exploring the Cognitive Benefits of a Blackcurrant-Based Supplement in Normobaric Hypoxia","The Efficacy of a Blackcurrant-based Nootropic Drink to Support Cognitive Functioning Under Normobaric Simulated High Altitude","Inclusion Criteria:\n\n* Willing and able to provide written informed consent (in English)\n* Aged 18-35\n* Male\n* Residing at a low altitude (\\\u003C500m)\n\nExclusion Criteria:\n\n* Diagnosed food allergy or intolerance to the investigational products or control products. (Blackcurrant, food allergen\u002F pine, tree-derived allergen\u002F l-theanine tree allergen (camellia sinensis))\n* Significant past medical and psychiatric history and ongoing chronic conditions such as, cardiovascular disease, respiratory disease, endocrine disorder (e.g. Diabetes mellites) and neurological and psychiatric conditions including brain injury or are colourblind.\n* Significant medication history or current prescription of medication or supplements known to affect cognition such as. Sedatives, stimulants, or herbal supplements high in anthocyanin and polyphenol content.\n* A positive result from the pre-screening sickle cell trait blood test.\n* An abnormal ECG reading.\n* A resting heart rate above 100bmp.\n* A blood pressure reading above 140\u002F90mmHg.\n* Subjects not willing and\u002F or not able to comply with the scheduled visits required for the study.\n* Not willing to provide blood samples.\n* Not classified as low risk based on the ACSM guidelines.","35 Years",{"count":374,"type":23},27,[26],"This study investigates the cognitive effects of Ārepa, a blackcurrant-based drink, under simulated high-altitude conditions (4,500m normobaric hypoxia for \\~180 minutes). Using a double-blind, randomised, placebo-controlled crossover design, participants will consume either the nootropic blackcurrant-based drink or a taste-matched placebo. Cognitive testing (\\~80 minutes) includes Trail-making, Stroop, N-back, Serial 7s\u002F3s, and RVIP tasks. Physiological measures (heart rate, SpO₂, blood) and biomarkers (MAO-B, BDNF, hsCRP, S100B, Prolactin, C3G, Sarmentosin) will be assessed. Scales will evaluate mood, wellbeing, and perceived effects. The aim is to determine if the nootropic drink can support cognitive function in hypoxic environments.",[30,378,379,380,381],"Executive Function (Cognition)","Working Memory","Hypoxia Induced Cognitive Impairment","Mood","2025-09-03",{"date":384,"type":51},"2025-09-10",{"date":386,"type":23},"2025-09-01",{"date":388,"type":23},"2027-10-01",{"name":390,"class":58},"Leeds Beckett University",{"id":392,"slug":393,"hasResults":11,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":17,"sex":66,"minAge":123,"maxAge":231,"enrollmentInfo":398,"targetDuration":4,"studyType":24,"phases":400,"briefSummary":401,"conditions":402,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":86},"100480892","use-muscadine-wine-nutraceuticals-to-improve-brain-health-cognition-and-mental-health-100480892","NCT05541887","Use Muscadine Wine Nutraceuticals to Improve Brain Health, Cognition, and Mental Health","Acute and Chronic Impacts of Muscadine Wine Polyphenols on Cognition, Memory, Mood, and Anxiety in Adults Over 50 Years of Age","Inclusion Criteria:\n\n* Healthy\n* BMI (18.5-29.9)\n* Body weight ≥110 pounds\n\nExclusion Criteria:\n\n* Pregnancy\n* Breast-feeding\n* Smokers\n* Diabetic\n* Heavy drinkers\n* Subjective but not clinically diagnosed cognitive impairment (Montreal cognitive assessment score \\\u003C26),\n* Inability to understand the cognitive function tasks\n* Intake of medication that might influence the outcome of the study (e.g. psychostimulant)\n* cannabis product user\n* Clinically diagnosed mental illnesses\n* Cardiovascular and neurological disorders\n* Uncontrolled hypertension",{"count":399,"type":23},25,[26],"Previous studies have shown that polyphenol-rich foods can positively affect cognitive functions, memory, and mood in humans. We hypothesize that both acute and chronic intake of muscadine wine polyphenols will improve cognitive performance and mood through regulating the HPA axis, alleviating inflammation and oxidative stress, and\u002For inhibiting monoamine oxidase activities",[30,102,381,403],"Anxiety","2025-06-09",{"date":406,"type":51},"2025-06-12",{"date":408,"type":51},"2023-08-30",{"date":410,"type":23},"2026-12",{"name":412,"class":58},"University of Florida",{"id":414,"slug":415,"hasResults":11,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":419,"eligibilityCriteria":420,"healthyVolunteers":17,"sex":66,"minAge":421,"maxAge":422,"enrollmentInfo":423,"targetDuration":4,"studyType":24,"phases":425,"briefSummary":426,"conditions":427,"keywords":431,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":86},"100525882","peanut-consumption-on-cognitive-weight-and-inflammation-100525882","NCT06127511","Peanut Consumption on Cognitive, Weight, and Inflammation","Peanut Consumption on Cognitive Performance, Weight Management, and Inflammation in Young Adolescents","PEANUTY","Inclusion Criteria:\n\nEligible participants will be young adolescents, boys and girls, aged between 10 and 12 years who attend regular primary schools in Barcelona. The schools will assist with the participant recruitment through the classes and after that, a total of one-hundred students will be randomly included in each group. In all cases, participation will be voluntary and informed consent will be obtained prior to the study.\n\nExclusion Criteria:\n\nThe exclusion criteria will be history of allergy or intolerance to peanuts, any medical conditions or dietary restrictions that would affect peanut consumption, being able to understand Spanish or Catalan, and use of antibiotics in the month prior to the study.","10 Years","12 Years",{"count":424,"type":23},200,[26],"A multi-school, two-arm parallel cluster-randomized controlled trial will be conducted in 200 healthy young adolescents from Barcelona (Spain) to evaluate the effect of peanut consumption on cognitive performance, weight management and inflammation. Schools willing to participate will be randomly assigned to either the intervention or the control group. After the recruitment, the participants will follow a peanut-free diet for two weeks. Both arms will receive a multidimensional educational intervention designed by the Gasol Foundation to promote healthy dietary habits based on Mediterranean diet recommendations, along with exercise performance, healthy sleeping habits and emotional knowledge. Half of the participants (intervention group) will consume 25 g of whole skin roasted peanuts as a daily snack to be incorporated into their diet for six months.",[30,428,429,430],"Inflammation","Weight Change, Body","Adolescents",[432,433,434,435,436,437,438,439,440,441,442,443],"peanut","cognitive","inflammation","weight","adolescent","obesity","gut microbiota","healthy dietary","physical activity","sleeping","behaviour habits","Mediterranean diet","2025-03-31",{"date":446,"type":51},"2025-04-03",{"date":448,"type":51},"2024-01-29",{"date":450,"type":23},"2025-12-31",{"name":452,"class":58},"University of Barcelona",{"id":454,"slug":455,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":457,"acronym":458,"eligibilityCriteria":459,"healthyVolunteers":11,"sex":66,"minAge":19,"maxAge":460,"enrollmentInfo":461,"targetDuration":4,"studyType":24,"phases":463,"briefSummary":464,"conditions":465,"keywords":466,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":86},"100562727","determining-which-regions-of-the-brain-are-active-during-flight-simulation-at-separate-timepoints-during-training-100562727","NCT06606925","Determining Which Regions of the Brain Are Active During Flight Simulation at Separate Timepoints During Training","fMRI Pilots","Inclusion Criteria:\n\n* Active Duty Military Pilots (Instructor Pilot Trainees or Remote Piloted Aircraft Trainees)\n* Age 18-54 years\n* Biological male or female\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Age \\> 60 years\n* Non-active-duty members\n* History of recurrent migraine headaches requiring chronic suppressive medication or prescription drug intervention more frequently than once per year.\n* History of head trauma or traumatic brain injury with any loss of consciousness or with confusion or amnesia of greater than five minutes.\n* History of eye trauma related to a metallic object unless the presence of residual metal has been previously excluded by x-ray.\n* Pregnancy\n* History of significant neurological disease including cerebrovascular disease, demyelinating disease, or infections of the central nervous system (encephalitis, meningitis).\n* History of medical conditions with potential neurological involvement such as obstructive sleep apnea, autoimmune disorders, etc.\n* History of seizures since age six.\n* Claustrophobia or intolerance of the MRI without medication.\n* Any medical contraindication to MRI (ex: foreign bodies, non-MRI compatible pacemaker, metal devices).","54 Years",{"count":462,"type":23},150,[26],"The overall objective is to identify the cognitive circuits associated with military aviator performance by analyzing what anatomic regions of the brain are functionally \"active\" (neuronal circuit) while being performing virtual flight simulations, the Precision Instrument Control Task (PICT). The flight simulation test will be conducted at two separate timepoints while the subject is receiving a Functional Magnetic Resonance Imaging (fMRI) scan to evaluate which anatomic and functional brain function is associated with precise performance. By scanning at multiple time points we aim to quantify changes in functional and anatomic connectivity that occur throughout the course of training.",[30],[467,468,300,469,30,470,75],"Pilots","Flight Simulator","Training","Neuroergonomics","2025-01-13",{"date":473,"type":51},"2025-01-15",{"date":475,"type":51},"2023-09-19",{"date":477,"type":23},"2026-09-18",{"name":479,"class":58},"The Geneva Foundation",{"id":481,"slug":482,"hasResults":11,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":17,"sex":66,"minAge":19,"maxAge":372,"enrollmentInfo":487,"targetDuration":4,"studyType":24,"phases":488,"briefSummary":489,"conditions":490,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":86},"100472157","clinical-study-to-evaluate-the-effects-of-two-novel-hydration-beverage-formulas-on-rehydration-in-healthy-adults-100472157","NCT05428228","Clinical Study to Evaluate the Effects of Two Novel Hydration Beverage Formulas on Rehydration in Healthy Adults","A Randomized, Placebo Controlled, Semi-Blind, Crossover Study to Evaluate the Effects of Two Novel Hydration Beverage Formulas on Rehydration in Healthy Adults","Inclusion Criteria:\n\n* Healthy adult male and female participants who are between 18 and 49 years of age (inclusive). Are in good general health (no active or uncontrolled diseases or conditions) and can ingest the assigned amount of fluid at each visit. Have a body mass index (BMI) between 17.0 and 29.9 kg\u002Fm2 (inclusive). Exercise regularly as per physical activity guidelines for Americans \\[structured exercise for a minimum of 150 cumulative minutes per week (low end) to 500 cumulative minutes of exercise per week (high-end)\\] and willing to maintain the same level of physical activity throughout the study period. Can maintain their exercise status at the beginning of the study throughout the study period. Can achieve a peak VO2 at screening that is at least 60% of their age and gender matched normative value per American College of Sports Medicine recommendations. Have normal or acceptable to the investigator vital signs (BP and HR) at screening. Individuals with childbearing potential: Agree to have urine pregnancy test performed on each trial day. Able to agree to the requirements and restrictions of this study, willing to give voluntary consent, able to understand and read the questionnaires, and carry out all study-related procedures.\n\nExclusion Criteria:\n\n* Female participants who are lactating, pregnant or planning to become pregnant during the study. Carry a diagnosis of diabetes. Weigh less than or equal to 80 pounds at any visits. Answer \"yes\" to any of the questions asked on the screening questionnaire (Appendix 10.2.1). Have a history of a diagnosis of celiac disease, chronic pancreatitis, steatorrhea, unstable thyroid disease, major affective disorder, psychiatric disorder that required hospitalization in the prior year, immune disorder (i.e., HIV\u002FAIDS), cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit). Use any dietary supplements that may impact hydration status within the 30 days prior to the baseline visit (Familiarization Trial\u002FVisit 2). Participants must observe a 30-day washout period of no supplementation to be eligible. Consume more than two standard alcoholic drinks per day. Use of inhalables, smokables, or the like (e.g., cigarettes, vaporizers, water pipes, or cannabis) within 30 days prior to the first dose of the study product or for the duration of the study. Have a medical condition that may impact ability to exercise or ability to ingest prescribed fluid volume. Smoking tobacco products.",{"count":5,"type":23},[26],"The aim of the clinical trial is to evaluate the efficacy of two novel hydration products on rehydration following exercise.",[491,492,493,494,30],"Dehydration","Rehydration","Exercise Performance","Exercise Recovery","2024-07-26",{"date":497,"type":51},"2024-07-29",{"date":499,"type":51},"2022-10-01",{"date":501,"type":23},"2024-09-01",{"name":503,"class":58},"Liquid I.V."]